Virpax Pharma Reported FY23 EPS Loss of $(12.97) Vs $(9.20) Est, Cash Balance of $9.1M
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharma (VRPX) reported a fiscal year 2023 earnings per share (EPS) loss of $(12.97), which is wider than the estimated loss of $(9.20). The company also reported a cash balance of $9.1 million.
March 26, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Virpax Pharma reported a larger than expected FY23 EPS loss of $(12.97) compared to the estimated $(9.20), with a cash balance of $9.1M.
The reported EPS loss being significantly wider than the estimated loss suggests underperformance and may lead to negative investor sentiment in the short term. The cash balance provides some insight into the company's liquidity, but the larger loss could overshadow this aspect.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100